相关实验视频
Updated: Jul 29, 2026
06:20
Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
2.6K
多维分析确定了胰腺癌研究的高优先级基因
Zeribe C Nwosu1, Heather M Giza1, Maya Nassif1
1Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, Michigan, USA.
JCI insight
|January 8, 2025
概括
研究人员在胰腺癌 (PDAC) 中发现了3900多个持续改变的基因,其中许多基因以前没有被描述过. 这些基因为这种致命疾病提供了潜在的新治疗点和生物标志物.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 胰腺管腺癌 (PDAC) 是一种高度致命的癌症,以其耐药性而闻名.
- 在患者队伍中识别持续改变的基因对于发现有效的治疗点至关重要.
研究的目的:
- 在多个数据集中在PDAC中识别一致的上调和下调基因.
- 描述这些基因的功能,组织特异性和与临床特征的关联.
- 探索它们作为治疗标和生物标记物的潜力.
主要方法:
- 对5个人类PDAC微阵列数据集的分析,以确定一致差异表达的基因 (调整后P<0.05在>=4个数据集).
- 验证和进一步分析使用额外的数据集,包括单细胞RNA测序.
- 途径丰富,组织特异性,本质性和与癌症特征的相关性 (亚型,增殖,转移,生存).
主要成果:
- 在PDAC中确定了2,010个持续上调和1,928个下调的基因.
- 超过50%的这些基因在PDAC中没有表征.
- 改变的基因参与了细胞循环,免疫,新陈代谢,信号和表观遗传调节;细胞循环和糖解受影响最大.
- 抑制几个上调的基因损害了PDAC细胞活力.
- 升级的基因预测了对表观遗传蛋白抑制的敏感性,这与凝胺一起破坏了瘤生长.
结论:
- 这项研究确定了PDAC中大量的新型,持续改变的基因.
- 这些基因代表了作为治疗标和生物标志物进一步研究的有希望的候选人.
- 向表观遗传蛋白与化疗相结合,显示了PDAC治疗的潜力.
相关概念视频
01:33Cancer-Critical Genes I: Proto-oncogenes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...